StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) stock

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.44+0.04 (+10.08%)

Close on Nov 18, 2026Market cap $1.64MP/E –Yield –

Kairos Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kairos Pharma's operating income for the twelve months ending Sep 30, 2026 was -$6.53M. For fiscal 2025 it was -$5.57M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.57M–
FY2024Dec 31, 2024-$2.34M–
FY2023Dec 31, 2023-$1.71M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.01M–
Q2 FY2026Jun 30, 2026-$1.42M–
Q1 FY2026Mar 31, 2026-$1.69M–
Q4 FY2025Dec 31, 2025-$1.42M–
Q3 FY2025Sep 30, 2025-$1.44M–
Q2 FY2025Jun 30, 2025-$1.46M–
Q1 FY2025Mar 31, 2025-$1.27M–
Q4 FY2024Dec 31, 2024-$1.45M–
Q3 FY2024Sep 30, 2024-$383.00K–
Q2 FY2024Jun 30, 2024-$222.00K–
Q1 FY2024Mar 31, 2024-$287.00K–
Q4 FY2023Dec 31, 2023-$1.09M–
Q3 FY2023Sep 30, 2023-$287.00K–

More Kairos Pharma figures

See a number that looks wrong?